Patent ID: 11890293
Assignee: GLYCOM A/S
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 0:
1. A method comprising:
selecting an effective amount of one or more human milk oligosaccharides (HMOs) selected from:
fucosylated HMOs 2′-fucosyllactose (2′-FL), 3-fucosyllactose (3-FL), difucosyllactose (DFL), and lacto-N-fucopentaose I (LNFP-I);
non-fucosylated HMOs lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), 3′,6-disialyllacto-N-tetraose (DSLNT), 6′-sialyllactose (6′-SL), and 3′-sialyllactose (3′-SL); and
mixtures thereof, in a total daily dosage of HMOs from about 3 g to about 10 g that is effective to increase Bifidobacterium adolescentis in the gut microbiota of a non-infant human during an initial treatment period;

selecting a non-infant patient having an obesity-related metabolic disorder and being diagnosable with one or more of obesity, obesity-induced pre-diabetes, and obesity-induced type 2 diabetes; and
increasing the relative abundance of Bifidobacterium adolescentis in the non-infant patient and improving in the non-infant patient at least one condition selected from increased insulin sensitivity, reduced insulin resistance, improved gut barrier function, and reduction of metabolic inflammation by providing the total daily dosage of the selected one or more HMOs for consumption by the non-infant patient during the initial treatment period.